Legislation aims to increase research on lung cancer among women, improve screening access

[ad_1]

oncology.pencis.com/” target=”_blank”> GO2 for Lung cancer praised lawmakers in the House and Senate for introducing a bipartisan bill that would increase Research focus on the impact of lung cancer among women.

oncology.pencis.com/” target=”_blank”>The Women and Lung cancer Research and Preventive Services Act of 2023 also aims to expand access to screening services and elevate national awareness of the disease, which remains the leading cause of cancer death among women.

oncology.pencis.com/” target=”_blank”>
oncology.pencis.com/” target=”_blank”>
oncology.pencis.com/” target=”_blank”>

oncology.pencis.com/” target=”_blank”>

oncology.pencis.com/” target=”_blank”>
oncology.pencis.com/” target=”_blank”>
oncology.pencis.com/” target=”_blank”>

oncology.pencis.com/” target=”_blank”>The Women and Lung cancer Research and Preventive Services Act of 2023 aims to increase Research on women and lung cancer, as well as access to preventive services. Image: Adobe Stock

oncology.pencis.com/” target=”_blank”>“The time is now to transform survivorship for women impacted by lung cancer,” Laurie Fenton Ambrose, president and CEO of GO2 for Lung cancer, said in a press release from the organization. “This has been a core priority of ours for years and we are grateful to these elected leaders who are accelerating lifesaving change for our community.”

oncology.pencis.com/” target=”_blank”>According to the release, the legislation calls for the secretary of health and human services, secretary of defense and secretary of veterans affairs to evaluate the status of and seek opportunities related to:

  • oncology.pencis.com/” target=”_blank”>Improved access to lung cancer preventive services; and
  • oncology.pencis.com/” target=”_blank”>A national public awareness and education campaign on lung cancer.

oncology.pencis.com/” target=”_blank”>On average, lung cancer receives $3,580 per death in NIH Research funding, compared with more than $19,050 per death for breast cancer, according to the release.

oncology.pencis.com/” target=”_blank”>“Lung cancer develops differently in women and men,” Ambrose said. “There are sex differences in many facets of the disease, including risk factors, clinical characteristics, progression and length of survival. Yet Research on these differences is far from conclusive — and woefully lacking. The result has limited opportunities to improve preventive, diagnostic and therapeutic practices. Increasing the investment in women’s health Research will reverse this this trend.”

[ad_2]

Research.html”>Source link

Cancer-killing pill that annihilates tumours hailed as ‘holy grail’ breakthrough

[ad_1]

oncology.pencis.com/” target=”_blank”> 

oncology.pencis.com/” target=”_blank”>

oncology.pencis.com/” target=”_blank”>

oncology.pencis.com/” target=”_blank”>Scientists have developed a ‘holy grail’ molecule that kills all solid cancer tumours, leaving healthy cells unaffected.

oncology.pencis.com/” target=”_blank”>The team at the City of Hope, one of the largest cancer Research and treatment organisations in the US, made the breakthrough against the proliferating cell nuclear antigen (PCNA) protein.

oncology.pencis.com/” target=”_blank”>In a mutated form PCNA is critical in DNA replication and repair of all expanding tumours, but a molecule developed by the team, AOH1996, targets and kills the mutated PCNA.

oncology.pencis.com/” target=”_blank”>Previously PCNA was thought too challenging to be a target for therapy, but preclinical Research shows AOH1996 seems to annihilate all solid tumours – without effects on other body cells.

oncology.pencis.com/” target=”_blank”>‘Results have been promising,’ said Dr Malkas. ‘AOH1996 can suppress tumor growth as a monotherapy or combination treatment in cell and animal models without resulting in toxicity.

oncology.pencis.com/” target=”_blank”>‘The investigational chemotherapeutic is currently in a Phase 1 clinical trial in humans at City of Hope.’

oncology.pencis.com/” target=”_blank”>The researchers have tested AOH1996 in more than 70 cancer cell lines and several normal control cells. They found the molecule selectively kills cancer cells by disrupting the normal cell reproductive cycle.

oncology.pencis.com/” target=”_blank”>In their Research, the team has found AOH1996 prevented cells with damaged DNA from dividing and from making a copy of faulty DNA, causing cancer cell death – known as apoptosis – but it did not interrupt healthy stem cells.

oncology.pencis.com/” target=”_blank”>‘Conference-registration-gbp/”>Undruggable’, but City of Hope was able to develop an investigational medicine for a challenging protein target.

oncology.pencis.com/” target=”_blank”>‘We discovered that PCNA is one of the potential causes of increased nucleic acid replication errors in cancer cells.

oncology.pencis.com/” target=”_blank”>‘Now that we know the problem area and can inhibit it, we will dig deeper to understand the process to develop more personalised, targeted cancer medicines.’

oncology.pencis.com/” target=”_blank”>Experiments showed that the investigational pill made cancer cells more susceptible to chemical agents that cause DNA or chromosome damage, hinting that AOH1996 could become a useful tool in combination therapies and new chemotherapeutics.

oncology.pencis.com/” target=”_blank”>Professor Daniel Von Hoff, co-author, added: ‘City of Hope has world leaders in cancer Research. They also have the infrastructure to drive translational drug discovery from the laboratory into the clinic for patients in need.’

oncology.pencis.com/” target=”_blank”>The Phase 1 clinical trial began in October.

oncology.pencis.com/” target=”_blank”>As a next step, the researchers will look to better understand the mechanism of action to further improve the ongoing clinical trial in humans.

oncology.pencis.com/” target=”_blank”>The team is continuing to investigate the mechanisms that make this cancer-stopping pill work in animal models, while a Phase 1 clinical trial test is also ongoing in humans.

oncology.pencis.com/” target=”_blank”>However, it is not yet known if the drug will continue to be taken in pill form once fully developed and approved for use.

oncology.pencis.com/” target=”_blank”>The new therapy is the result of 20 years of Research and development – and is named after Anna Olivia Healey (AOH), a young girl born in 1996 who unfortunately was not able to beat cancer.

oncology.pencis.com/” target=”_blank”>‘Most targeted therapies focus on a single pathway, which enables wily cancer to mutate and eventually become resistant,’ said team leader Dr Linda Malkas, a professor in City of Hope’s department of molecular diagnostics and experimental therapeutics.

oncology.pencis.com/” target=”_blank”>‘PCNA is like a major airline terminal hub containing multiple plane gates.

oncology.pencis.com/” target=”_blank”>‘Data suggests PCNA is uniquely altered in cancer cells, and this fact allowed us to design a drug that targeted only the form of PCNA in cancer cells.

oncology.pencis.com/” target=”_blank”>‘Our cancer-killing pill is like a snowstorm that closes a key airline hub, shutting down all flights in and out only in planes carrying cancer cells.’

oncology.pencis.com/” target=”_blank”>The study, published in the journal Cell Chemical Biology, claims AOH1996 has been effective in preclinical Research treating cells derived from breast, prostate, brain, ovarian, cervical, skin and lung cancers.

#prostatecancer #lungcancer #coloncancer #ovariancancer #pancreaticcancer #leukemia #Conference-registration-usd/”>Lymphoma #OncologyConference #CancerResearch #OncologyAwards #CancerTreatment #OncologyCommunity #CancerCare #OncologyEducation #CancerSurvivorship #OncologyInnovation #CancerAwareness #OncologyLeadership #CancerPrevention #OncologyExcellence #CancerBreakthroughs #OncologyCollaboration #CancerAdvancements #OncologyImpact #CancerPatientsFirst #OncologyFuture #OncologyInspiration #CancerFighters #OncologyHeroes #CancerAwarenessMonth #OncologyProgress #CancerSolutions #OncologyExperts #CancerSurvivors #shorts #shortsvideo #cancerConference #OncologyConference #pencis #oncologyconference #CardioOnc #radonc #medonc #caxtx #GeriOnc #psyonc #oncorn #hsronc #camets #cancer #fuckcancer #cancersucks #breastcancerawareness #breastcancer #cancermemes #cancerousmemes #cancersurvivor #cancerawareness #cancerdemama #breastcancerawarenessmonth #cancerresearch #fightcancer #childhoodcancerawareness #beatcancer #childhoodcancer #cancerseason #breastcancersurvivor #cancerfree #cancerfighter #cancerous #fcancer #cancerwarrior #teamcancer #ovariancancer #americancancersociety #standuptocancer #cancerresearchuk #cancersupport #skincancer #cancermeme #cancer #feminismiscancer #curecancer #anticancer #cancerzodiac #prostatecancer #cancers #fucancer #pediatriccancer #cancerawareness #beatcancer #cancersucks #cancerresearch #cancerfighter #cancerwarrior #cancertreatment #cancersurvivor #cancerprevention #cancerawarenessmonth #cancerpatientsupport #breastcancer #prostatecancer #lungcancer #coloncancer #ovariancancer #pancreaticcancer #leukemia #Conference-registration-usd/”>Lymphoma #melanoma #braincancer #childhoodcancer #cancerfree #oncology #cancercare #cancerdiagnosis #cancerribbon #cancerjourney

[ad_2]

cancer-killing-pill-that-annihilates.html”>Source link

New immunotherapy drug shows promise as cancer treatment, research suggests

[ad_1]

oncology.pencis.com/” style=”clear: right; float: right; margin-bottom: 1em; margin-left: 1em;”>

oncology.pencis.com/”>A new class of Conference-registration-euro/”>immunotherapy could offer hope to cancer patients who do not respond to existing treatments, Research suggests.

oncology.pencis.com/”>The study found the drug, called MOv18 IgE, shrank a tumour in a patient with ovarian cancer and reported that it was well tolerated in patients.

oncology.pencis.com/”>The scientists suggest their findings could pave the way for a completely new type of anti-cancer drug for people with Award-call-for-profile/”>Chemotherapy-resistant cancers.

oncology.pencis.com/”>The study by researchers from King’s College London and Guy’s and St Thomas’ NHS Foundation Trust, and funded by cancer Research UK, tested whether a type of antibody called IgE could be used to treat human cancer.oncology.pencis.com/”/>

oncology.pencis.com/”>The results pave the way to development of an entirely new class of anti-cancer drug for people with Award-call-for-profile/”>Chemotherapy-resistant cancers

                                                         oncology.pencis.com/”>Professor James Spicer, King’s College London

oncology.pencis.com/”>Conference-registration-euro/”>immunotherapy works by stimulating the body’s natural defence system to attack cancer.

oncology.pencis.com/”>Existing antibody drugs used in cancer belong to an antibody type called IgG, but IgE antibodies have not been tested in humans before.

oncology.pencis.com/”>IgE antibodies evolved to target parasites like worms and flukes, and IgG antibodies are involved in attacking bacteria and viruses in the body.

oncology.pencis.com/”>Lead author on the study, Professor James Spicer, professor of experimental cancer medicine at King’s College London and Consultant in Medical oncology at Guy’s and St Thomas’ NHS Foundation Trust (GSTT), said: “IgE is a completely new form of antibody therapy which has shown great promise in this Phase I trial.

oncology.pencis.com/”>“Our findings show that the drug was well tolerated in patients and shrunk a cancerous tumour in a patient with ovarian cancer.

oncology.pencis.com/”>“The results pave the way to development of an entirely new class of anti-cancer drug for people with Award-call-for-profile/”>Chemotherapy-resistant cancers.oncology.pencis.com/”>“The immunology expertise in King’s College London laboratories allowed us to undertake this trial of a completely new form of antibody therapy.”oncology.pencis.com/”/>

oncology.pencis.com/”>Conference-registration-euro/”>immunotherapy has shown enormous potential recently but there are still people with cancer who do not respond to conventional therapy
                                                              oncology.pencis.com/”>Professor Sophia Karagiannis, King’s College London

oncology.pencis.com/”>Co-author Sophia Karagiannis, professor of translational cancer immunology and Conference-registration-euro/”>immunotherapy at King’s College London, said: “Conference-registration-euro/”>immunotherapy has shown enormous potential recently but there are still people with cancer who do not respond to conventional therapy.

oncology.pencis.com/”>“This trial builds on our previous work into the biology of IgE, including experiments in the laboratory suggesting that IgE could be an effective treatment that can offer additional benefits to complement those of established IgG antibodies in the clinic.

oncology.pencis.com/”>“While we are still in the early stage of trials, our next steps will be to evaluate IgE in larger and different groups of patients and to continue studying how IgE antibodies are able to wake up the patient’s immune system to fight different cancers.”

#prostatecancer #lungcancer #coloncancer #ovariancancer #pancreaticcancer #leukemia #Conference-registration-usd/”>Lymphoma #OncologyConference #CancerResearch #OncologyAwards #CancerTreatment #OncologyCommunity #CancerCare #OncologyEducation #CancerSurvivorship #OncologyInnovation #CancerAwareness #OncologyLeadership #CancerPrevention #OncologyExcellence #CancerBreakthroughs #OncologyCollaboration #CancerAdvancements #OncologyImpact #CancerPatientsFirst #OncologyFuture #OncologyInspiration #CancerFighters #OncologyHeroes #CancerAwarenessMonth #OncologyProgress #CancerSolutions #OncologyExperts #CancerSurvivors #shorts #shortsvideo #cancerConference #OncologyConference #pencis #oncologyconference #CardioOnc #radonc #medonc #caxtx #GeriOnc #psyonc #oncorn #hsronc #camets #cancer #fuckcancer #cancersucks #breastcancerawareness #breastcancer #cancermemes #cancerousmemes #cancersurvivor #cancerawareness #cancerdemama #breastcancerawarenessmonth #cancerresearch #fightcancer #childhoodcancerawareness #beatcancer #childhoodcancer #cancerseason #breastcancersurvivor #cancerfree #cancerfighter #cancerous #fcancer #cancerwarrior #teamcancer #ovariancancer #americancancersociety #standuptocancer #cancerresearchuk #cancersupport #skincancer #cancermeme #cancer #feminismiscancer #curecancer #anticancer #cancerzodiac #prostatecancer #cancers #fucancer #pediatriccancer #cancerawareness #beatcancer #cancersucks #cancerresearch #cancerfighter #cancerwarrior #cancertreatment #cancersurvivor #cancerprevention #cancerawarenessmonth #cancerpatientsupport #breastcancer #prostatecancer #lungcancer #coloncancer #ovariancancer #pancreaticcancer #leukemia #Conference-registration-usd/”>Lymphoma #melanoma #braincancer #childhoodcancer #cancerfree #oncology #cancercare #cancerdiagnosis #cancerribbon #cancerjourney

[ad_2]

Conference-registration-euro/”>immunotherapy-drug-shows-promise-as.html”>Source link

Enhertu Shows Promise for Several Types of HER2-Positive Cancer

[ad_1]

oncology.pencis.com/” target=”_blank”>

oncology.pencis.com/” target=”_blank”>

oncology.pencis.com/” target=”_blank”>

oncology.pencis.com/” target=”_blank”>The antibody-drug conjugate Enhertu (trastuzumab deruxtecan), which is currently approved for advanced breast, lung and stomach cancer, is also effective for people with several other types of tumors that express HER2, according to Research presented at the 2023 American Society of Clinical oncology (ASCO) Annual Meeting.

oncology.pencis.com/” target=”_blank”>In the Phase II DESTINY-PanTumor02 study, overall response rates were 45% for ovarian cancer, 50% for cervical cancer and 58% for endometrial but only reached 4% for hard-to-treat pancreatic cancer. Rates were higher for tumors with stronger HER2 expression. A related study saw a 38% response rate for advanced colorectal cancer.

oncology.pencis.com/” target=”_blank”>“HER2 is present in many cancer types, such as breast, gastric, lung, gynecologic and urothelial cancers, and patients with HER2-expressing, hard-to-treat cancers need new treatment options,” lead investigator Funda Meric-Bernstam, MD, of the University of Texas MD Anderson cancer Center, said in an ASCO press release.

oncology.pencis.com/” target=”_blank”>“These results advance our clinical understanding of HER2 expression, reaffirm HER2 as an actionable biomarker across a broad range of tumor types and show that trastuzumab deruxtecan could potentially provide a new treatment option for patients with advanced disease across these tumors.”

oncology.pencis.com/” target=”_blank”>Enhertu, from Daiichi Sankyo and AstraZeneca, is an antibody-drug conjugate, a new type of treatment that uses antibodies to deliver toxic Award-call-for-profile/”>Chemotherapy drugs directly to tumors. Enhertu combines the monoclonal antibody trastuzumab (Herceptin), which targets HER2, with a topoisomerase inhibitor as a payload. Tumors that strongly express HER2—a receptor for a protein that promotes cell growth—are classified as HER2-positive.

oncology.pencis.com/” target=”_blank”>The Food and Drug Administration initially granted accelerated approval of Enhertu for the treatment of inoperable or metastatic HER2-positive breast cancer in 2019. At last year’s ASCO meeting, researchers reported that Enhertu also works well for breast tumors with low HER2 expression, leading to approval for that indication and expanding the eligible patient population. Enhertu is also approved for HER2-positive non-small-cell lung cancer and gastric or gastroesophageal junction cancer. This suggests that people with other types of HER2-expressing tumors could benefit as well.

oncology.pencis.com/” target=”_blank”>The open-label DESTINY-PanTumor02 trial (NCT04482309) enrolled 267 previously treated patients with HER2-expressing locally advanced or metastatic biliary tract, bladder (urothelial), cervical, endometrial, ovarian, pancreatic or other tumors. They either had progressed after at least one systemic treatment or had no available treatment options. Seventy-five patients had tumors classified as IHC 3+ (high HER2 expression), while 125 were classified as IHC 2+ (moderate HER2 expression). The participants received Enhertu at a dose of 5.4 milligrams per kilogram by intravenous infusion every three weeks.

oncology.pencis.com/” target=”_blank”>After a median follow-up period of 9.7 months, objective response rates, indicating tumor shrinkage or remission, varied widely across cancer types and were generally better for tumors with higher HER2 expression:

  • oncology.pencis.com/” target=”_blank”>Endometrial cancer: 58% overall, 85% for IHC 3+, 47% for IHC 2+
  • oncology.pencis.com/” target=”_blank”>Cervical cancer: 50% overall, 75% for IHC 3+, 40% for IHC 2+
  • oncology.pencis.com/” target=”_blank”>Ovarian cancer: 45% overall, 63% for IHC 3+, 37% for IHC 2+
  • oncology.pencis.com/” target=”_blank”>Bladder cancer: 39% overall, 56% for IHC 3+, 35% for IHC 2+
  • oncology.pencis.com/” target=”_blank”>Biliary tract cancer: 22% overall, 56% for IHC 3+, 0% for IHC 2+
  • oncology.pencis.com/” target=”_blank”>Pancreatic cancer: 4% overall, 0% for IHC 3+, 5% for IHC 2+
  • oncology.pencis.com/” target=”_blank”>Other tumor types: 30% overall, 44% for IHC 3+, 19% for IHC 2+.

oncology.pencis.com/” target=”_blank”>Across all tumor types, the median duration of response was 11.8 months, rising to 22.1 months for people with IHC 3+ tumors.

oncology.pencis.com/” target=”_blank”>In a related presentation, researchers reported results from the Phase II DESTINY-CRC02 trial (NCT04744831), showing an overall response rate of 38% for people with locally advanced or metastatic colorectal cancer who were treated with the optimal 5.4 mg/kg dose. Here, too, the response rate was higher for patients with IHC 3+ tumors (47%) versus IHC 2+ tumors (6%). The median duration of response was 5.5 months, the median progression-free survival time was 5.8 months and the median overall survival time was 13.4 months.

oncology.pencis.com/” target=”_blank”>Treatment with Enhertu was generally safe, though side effects were common. The most frequently reported severe (Grade 3 or higher) treatment-related adverse events in DESTINY PanTumor02 were white Blood cell deficiency (19%), Award-nomination/”>Anemia (9%), fatigue (6%) and platelet deficiency (5%). Twenty people (8%) developed treatment-related interstitial lung disease or pneumonitis (lung inflammation). About 12% of participants stopped treatment due to side effects.

oncology.pencis.com/” target=”_blank”>“This study provides data for an unmet need for patients who have exhausted standard therapeutic options with tumors that overexpress HER2 for which no drug is yet approved,” said ASCO expert Bradley McGregor, MD, of the Dana-Farber cancer Institute. “While additional follow-up is needed, there is robust activity across multiple HER2-expressing tumors with over 50% response rate in those with the highest levels of HER2 expression coupled with an encouraging safety profile. Trastuzumab deruxtecan could provide a new treatment option for these patients.”

oncology.pencis.com/” target=”_blank”>Click here to ready the DESTINY-PanTumor02 and DESTINY-CRC02 study abstracts.
Click here for more reports from ASCO 2023.
Click here to learn more about pancancer treatment.


    oncology.pencis.com/” target=”_blank”>Read More About:

    oncology.pencis.com/” target=”_blank”>

  • #antibody-drug conjugate
  •  

  • #biliary tract cancer
  •  

  • #bladder cancer
  •  

  • #cancer treatment
  •  

  • #cervical cancer
  •  

  • #colon cancer
  •  

  • #colorectal cancer
  •  

  • #endometrial cancer
  •  

  • #Enhertu
  •  

  • #ovarian cancer
  •  

  • #pancreatic cancer
  •  

  • #targeted therapy

[ad_2]

Source link

Drug shortages’ effects on cancer research may be felt for years to come

[ad_1]

oncology.pencis.com/” target=”_blank”> The United States is in the midst of some of the worst cancer drug shortages in history, affecting thousands of patients across the country who face delayed or cancelled Award-call-for-profile/”>Chemotherapy appointments. But these shortages aren’t just bad for current patients, experts say; their effects on cancer Research may be felt for years to come.

oncology.pencis.com/” target=”_blank”>The National cancer Institute, the federal government’s main agency for cancer Research and training, told CNN that at least 174 of its 608 trials may be affected by the shortages. However, that number can’t account for other trials that rely on these drugs or possible trials that researchers would like to start but can’t.

oncology.pencis.com/” target=”_blank”>For a mix of complex reasons, many cancer drugs have gone into and out of shortage for years, experts say, but at least 25 are now in shortage, according to the American Society of Health-System Pharmacists. Two in particular — carboplatin and cisplatin — may be hurting Research the most because they are used with such a wide variety of cancers. Cisplatin and other platinum-based drugs are prescribed for 10% to 20% of all cancer patients, according to the National cancer Institute.

oncology.pencis.com/” target=”_blank”>In 2016, when Vice President Joe Biden launched the cancer Moonshot to “accelerate the rate of progress against cancer,” cutting-edge Research was supposed to become a national priority, but with a record number of cancer drugs in shortage, it’s become extremely difficult to conduct even basic Research.

oncology.pencis.com/” target=”_blank”>“With drug shortages, trials have become almost like an impossible task. You start asking yourself, ‘why am I doing this? Should I get a new job?’ ” asked Dr. Shadia Jalal.

oncology.pencis.com/” target=”_blank”>At the Indiana University Melvin and Bren Simon Comprehensive cancer Center, Jalal has overseen several clinical trials that have improved patients’ chances of beating their cancer. She’s also an associate professor of medicine in the Division of Hematology/oncology at IU School of Medicine; she directs Research priorities for Hoosier cancer Research Network, an independent nonprofit that specializes in early-phase multicenter investigator-initiated oncology clinical trials; and she cares for some of the country’s most vulnerable with the Veterans Administration.

oncology.pencis.com/” target=”_blank”>The shortages affect every aspect of her work, and she says they’ve really gotten to her.

oncology.pencis.com/” target=”_blank”>“Honestly, last week, I was so feeling down about it all,” Jalal said. “I was trying to remind myself of why I’m here.”

oncology.pencis.com/” target=”_blank”>Her trials have been able to continue, at least for now, but some researchers haven’t been as fortunate.

oncology.pencis.com/” target=”_blank”>“We’ve heard of institutions shutting down many new clinical trials that involve these drugs in shortage,” said Dr. Mark Fleury, policy principal with the American cancer Society cancer Action Network, a nonprofit, nonpartisan advocacy affiliate of the American cancer Society. Fleury said the issue has not gotten as much attention as the shortages’ effects on individual patients, but it has put the country’s push for better cancer medicine in real jeopardy.

oncology.pencis.com/” target=”_blank”>“Obviously, if you’re not doing the Research for the next best drug, that’s causing ramifications that we may not fully feel for a few years to come,” Fleury said.

oncology.pencis.com/” target=”_blank”>Dmitry Walker, assistant director of pharmacy oncology and investigational drug services at WVU Medicine, said his institution would love to offer a trial for people with bladder cancer using Bacillus Calmette-Guérin (BCG), a treatment that has showed real promise, but a yearslong limited supply makes it impossible.

oncology.pencis.com/” target=”_blank”>BCG is not on the US Food and Drug Administration’s drug shortage list, but the American Society of Health-System Pharmacists lists it as in shortage because drugmaker Merck has instituted tight controls while demand exceeds supply.

oncology.pencis.com/” target=”_blank”>“We’ve actually not been able to open a clinical trial like that, because you have to guarantee you’ll have enough cycles of treatments for them. And we don’t get enough allocation from the manufacturer even to meet our regular patient demand,” Walker said. “I know it’s been very frustrating for our urology physicians, because there’s definitely patients that would benefit from this clinical trial.”

oncology.pencis.com/” target=”_blank”>The National cancer Institute says that none of its clinical trials have had to close or have been put on hold because of the shortages but that some sites may not be able to enroll patients, and not all sites will be affected at the same time.

oncology.pencis.com/” target=”_blank”>“We are in close communication with clinical trials sites to monitor the situation and will provide updates as new data are available,” the institute told CNN in an email.

oncology.pencis.com/” target=”_blank”>Novel drugs typically aren’t the problem for researchers, because pharmaceutical companies can usually supply those to investigators. The problem lies with the drugs that scientists often use in comparison or conjunction with the novel treatment. They’re the medicines that doctors currently use to treat patients, and they’re often generics.

oncology.pencis.com/” target=”_blank”>A survey of major cancer centers published last month found that 93% couldn’t find enough carboplatin, and 70% had cisplatin shortages, according to the National Comprehensive cancer Network. At the beginning of June, the Biden administration worked with China on a special allowance to import cisplatin to help ease the shortage, but the drug remains on the FDA’s shortage list.

oncology.pencis.com/” target=”_blank”>Dr. Lawrence Feldman, a hematology and oncology specialist who has managed cancer drug trials at the University of Illinois Medical Center in Chicago, is recruiting patients for part of a multicenter lung cancer trial that Jalal’s center is also involved in.

oncology.pencis.com/” target=”_blank”>The trial uses carboplatin, which the center ran out of at one point. Swapping in cisplatin, which was more available, would require him to amend the trial.

oncology.pencis.com/” target=”_blank”>“That takes a fair amount of paperwork, and it has to be approved,” Feldman said. It’s time that researchers would rather dedicate to patients, but still, he went ahead with the switch. Just as he was trying to make the change, his center finally got a carboplatin shipment, but he filed the paperwork anyway, in case they have problems again.

oncology.pencis.com/” target=”_blank”>“You never know,” Feldman said. “These drug shortages come and go, and there’s no real rhyme or reason, and there seems to be no rhyme or reason in terms of which institutions have shortages. So it did affect us.”

oncology.pencis.com/” target=”_blank”>The FDA told CNN in an email Thursday that it is “working closely with a number of manufacturers, agencies, and others in the supply chain to understand, mitigate and prevent or reduce the impact of intermittent or increased demand of certain products.” The agency said it is also working across the government to find potential policies that may “ensure meaningful solutions.”

oncology.pencis.com/” target=”_blank”>In one sense, Feldman was lucky because he could swap out drugs. But with cancer, there are often no alternatives.

oncology.pencis.com/” target=”_blank”>Tenuous supplies have made it difficult to plan trials, a process that takes years. What drugs are plentiful now may be in shortage by the time the trial opens. Jalal worries about a trial conducted by a researcher whom she’s mentoring; Jalal was thrilled when it recently opened, but the trial requires a steady supply of carboplatin.

oncology.pencis.com/” target=”_blank”>“I hope to God we can enroll the study on time. We’ve been planning this for two years. I kept thinking to myself, ‘I hope it’s enrolled,’” she said.

oncology.pencis.com/” target=”_blank”>A delay in a trial isn’t just inconvenient. It can mean that the Research becomes irrelevant.

oncology.pencis.com/” target=”_blank”>“The field changes so quickly,” Jalal said. “With a delay, you find yourself asking ‘am I really going to be able to impact things by the time my study finishes?’ “

oncology.pencis.com/” target=”_blank”>Experts say cancer drug shortages probably won’t get better any time soon, and that’s be a big concern for the US, since it means denying help to people who could benefit from participating in these trials.

oncology.pencis.com/” target=”_blank”>“It’s honestly very, very stressful, and just taking care of people with cancer is already really stressful,” Jalal said. “I can’t imagine being a cancer patient right now. It’s very terrifying.”

#prostatecancer #lungcancer #coloncancer #ovariancancer #pancreaticcancer #leukemia #Conference-registration-usd/”>Lymphoma     #OncologyConference #CancerResearch #OncologyAwards #CancerTreatment #OncologyCommunity #CancerCare #OncologyEducation #CancerSurvivorship #OncologyInnovation #CancerAwareness #OncologyLeadership #CancerPrevention #OncologyExcellence #CancerBreakthroughs #OncologyCollaboration #CancerAdvancements #OncologyImpact #CancerPatientsFirst #OncologyFuture #OncologyInspiration #CancerFighters #OncologyHeroes #CancerAwarenessMonth  #OncologyProgress #CancerSolutions #OncologyExperts #CancerSurvivors  #shorts #shortsvideo #cancerConference #OncologyConference #pencis #oncologyconference  #CardioOnc  #radonc #medonc #caxtx #GeriOnc #psyonc #oncorn #hsronc #camets #cancer #fuckcancer #cancersucks #breastcancerawareness #breastcancer #cancermemes #cancerousmemes #cancersurvivor #cancerawareness #cancerdemama #breastcancerawarenessmonth #cancerresearch #fightcancer #childhoodcancerawareness #beatcancer #childhoodcancer #cancerseason #breastcancersurvivor #cancerfree #cancerfighter #cancerous #fcancer #cancerwarrior #teamcancer #ovariancancer #americancancersociety #standuptocancer #cancerresearchuk #cancersupport #skincancer #cancermeme #cancer #feminismiscancer #curecancer #anticancer #cancerzodiac #prostatecancer #cancers #fucancer #pediatriccancer  #cancerawareness #beatcancer #cancersucks #cancerresearch #cancerfighter #cancerwarrior #cancertreatment #cancersurvivor #cancerprevention #cancerawarenessmonth #cancerpatientsupport #breastcancer #prostatecancer #lungcancer #coloncancer #ovariancancer #pancreaticcancer #leukemia #Conference-registration-usd/”>Lymphoma #melanoma #braincancer #childhoodcancer #cancerfree #oncology #cancercare #cancerdiagnosis #cancerribbon #cancerjourney

[ad_2]

cancer.html”>Source link